Vascular Biogenics (VBLT) Stock Forecast, Price & News

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics or view top-rated stocks.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 688,000 shares, an increase of 32.4% from the April 15th total of 519,500 shares. Based on an average daily volume of 147,600 shares, the days-to-cover ratio is presently 4.7 days. Currently, 1.5% of the company's stock are sold short.
View Vascular Biogenics' Short Interest.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, May 17th 2022.
View our earnings forecast for Vascular Biogenics.

How can I listen to Vascular Biogenics' earnings call?

Vascular Biogenics will be holding an earnings conference call on Tuesday, May 17th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its earnings results on Wednesday, March, 23rd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.04. The biopharmaceutical company earned $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative net margin of 3,895.83% and a negative trailing twelve-month return on equity of 63.08%. During the same period last year, the business posted ($0.15) EPS.
View Vascular Biogenics' earnings history.

What price target have analysts set for VBLT?

4 brokers have issued 1-year target prices for Vascular Biogenics' stock. Their forecasts range from $4.00 to $7.00. On average, they expect Vascular Biogenics' stock price to reach $5.75 in the next year. This suggests a possible upside of 325.9% from the stock's current price.
View analysts' price targets for Vascular Biogenics or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:

• Prof. Dror Harats M.D., CEO & Director (Age 65)
• Dr. Eyal Breitbart Ph.D., Sr. VP of Research & Operations (Age 55)
• Dr. Naamit Sher Ph.D., Sr. VP of Drug Devel. & Regulatory Affairs (Age 68)
• Dr. Erez Feige M.B.A., Ph.D., Sr. VP of Bus. Operations (Age 48)
• Mr. Amos Ron, Company Sec. (Age 67)
• Mr. Samuel Backenroth, Chief Financial Officer (Age 38)
• Advocate Ayelet Horn, Gen. Counsel (Age 51)
• Deborah Scott, Managing Director of Financial Communications
• Dr. Tami Rachmilewitz M.D., Sr. VP of Clinical Devel. (Age 52)
• Mr. Matthew Trudeau M.Sc., Chief Commercial Officer

Who are some of Vascular Biogenics' key competitors?

Some companies that are related to Vascular Biogenics include Calliditas Therapeutics AB (publ) (CALT), Chimerix (CMRX), Heron Therapeutics (HRTX), Repare Therapeutics (RPTX), Esperion Therapeutics (ESPR), Inventiva (IVA), Thorne HealthTech (THRN), Rallybio (RLYB), Seres Therapeutics (MCRB), Khosla Ventures Acquisition (KVSA), Arbutus Biopharma (ABUS), Enochian Biosciences (ENOB), Generation Bio (GBIO), Fulcrum Therapeutics (FULC) and Rigel Pharmaceuticals (RIGL).
View all of VBLT's competitors.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include DLD Asset Management LP (0.79%), Envestnet Asset Management Inc. (0.05%), Advisor Group Holdings Inc. (0.05%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are buying Vascular Biogenics stock?

VBLT stock was bought by a variety of institutional investors in the last quarter, including DLD Asset Management LP, Envestnet Asset Management Inc., and Advisor Group Holdings Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.35.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $93.59 million and generates $770 thousand in revenue each year. The biopharmaceutical company earns $-29.92 million in net income (profit) each year or ($0.450010) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 41 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at [email protected], or via fax at 972-8993-5001.